U.S. Stem Cell (USRM) Stock Overview
Engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
USRM Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
U.S. Stem Cell, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0002 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 9,900.00% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | -97.06% |
| 5 Year Change | -99.83% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| USRM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | -0.6% |
| 1Y | 0% | 28.2% | 21.7% |
Return vs Industry: USRM underperformed the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: USRM underperformed the US Market which returned 21.3% over the past year.
Price Volatility
| USRM volatility | |
|---|---|
| USRM Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: USRM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine USRM's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | Mike Tomas | us-stemcell.com |
U.S. Stem Cell, Inc. engages in the research, development, and commercialization of stem cell and regenerative treatments in the United States and internationally. The company develops MyoCell, an autologous muscle stem cell therapy which is preparing for phase II/III clinical trials for the treatment of heart damage in heart failure patients; MyoCell SDF-1, an autologous cell therapy which completed the IND application for the treatment of chronic damage in the heart and enhancement of blood vessel formation; and AdipoCell, a clinical protocol and kit which is preparing for clinical trials for the treatment of chronic ischemic cardiomyopathy. It also offers regenerative medicine solutions to veterinarians; and training programs for physicians to perform bone marrow derived stem cell protocols.
U.S. Stem Cell, Inc. Fundamentals Summary
| USRM fundamental statistics | |
|---|---|
| Market cap | US$66.15k |
| Earnings (TTM) | -US$2.86m |
| Revenue (TTM) | US$82.05k |
Is USRM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| USRM income statement (TTM) | |
|---|---|
| Revenue | US$82.05k |
| Cost of Revenue | US$23.77k |
| Gross Profit | US$58.28k |
| Other Expenses | US$2.92m |
| Earnings | -US$2.86m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did USRM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/11 05:35 |
| End of Day Share Price | 2026/02/26 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
U.S. Stem Cell, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.